|Lapatinib (Code C26653)|
|Terms & Properties|
Preferred Name: Lapatinib
Definition: A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.
NCI-GLOSS Definition: A drug used with another anticancer drug to treat breast cancer that is HER2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. Lapatinib is also being studied in the treatment of other types of cancer. It is a type of ErbB-2 and EGFR dual tyrosine kinase inhibitor.
NCI Metathesaurus Link: C1506770 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
External Source Codes:
|CAS Registry Number||231277-92-2 (see NLM ChemIDplus info)|
|FDA UNII Code||0VUA21238F|
|ChEBI ID||CHEBI:49603 (see ChEBI info)|
|NSC Code||727989 (see NCI DTP info)|
|PubMedID Primary Reference||12214266 (see PubMed Primary Reference info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|